Therapies based on checkpoint inhibitors have emerged as promising strategies in the treatment of cancer patients. The selection of the most efficient combination of immunotherapies and an accurate prediction of cancer prognosis still remains challenging. Thus, scientists and clinicians need a deeper knowledge of the immune profile of each patient as well as a detailed characterization of the tumor microenvironment (TME) to develop targeted therapies.
Multiplex immunofluorescence (mIF) has become an important tool in the immune profiling of the TME. Multiplex IF assays allow the study of multiple markers in the same tissue sample preserving the spatial information of tissue morphology. From basic to clinical research, mIF enables the discovery of complex cell interactions as well as the identification of predictive biomarkers to monitor the patient’s response to immunotherapy.
Please tell us a bit about yourself to unlock this content.Unlock content